Previous close | 50.89 |
Open | 51.00 |
Bid | 49.77 x 100 |
Ask | 50.01 x 100 |
Day's range | 49.60 - 51.00 |
52-week range | 15.76 - 51.29 |
Volume | |
Avg. volume | 829,049 |
Market cap | 3.925B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.69 |
Earnings date | 09 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 61.08 |
Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety and Efficacy Findings SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, includin
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 9th @ 4:30 PM ETDomestic:1-888-886-7786International:1-416-764-8658Conference ID: 71864759 Participa
SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 121,300 shares of its common stock to ten new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements m